We currently have more than 15 active drug discovery and/or development programs. Restructuring Components of Results of Operations Revenue Research and Development Expenses General and Administrative Expenses Interest Income Other income (expense), net consists primarily of gains and losses resulting from changes to currency exchange rates. Income Taxes Comparison of Years Ended December 31, 2022 and 2021 Revenue The increase in revenue of $15.9 million for 2022 compared to 2021 was primarily due to: • • • • A decrease in revenue from Amgen under the Amgen Agreement driven by lower percentage of completion of the CX-904 program in the current year due to an increase in projected hours-to-completion.